Julia Rotow, MD

Articles

Exploring the TROPION-Lung04 Study

July 2nd 2024

Benjamin Levy, MD, presents an overview of the TROPION-Lung04 study in the first-line setting, focusing on the toxicity profile and potential impact on clinical practice.

Role of Antibody-Drug Conjugates in NSCLC Treatment: Insights from EVOKE-02

June 24th 2024

Benjamin Levy, MD, leads discussion on the promising potential of antibody-drug conjugates (ADCs) in treating non-small cell lung cancer (NSCLC) with non-actionable mutations, while Helena A. Yu, MD, presents an overview of the EVOKE-02 study, emphasizing key efficacy and safety data that could significantly impact the current treatment landscape.

Treatment Strategies for NSCLC with Non-Actionable Mutations

June 24th 2024

Mark Socinski, MD; Helena A. Yu, MD; Zosia Piotrowska, MD, MHS; Julia Rotow, MD; and Benjamin Levy, MD, provide a concise overview of current first-line treatment options for non-small cell lung cancer (NSCLC), including their approaches for NSCLC with non-actionable mutations and the influence of PD-L1 tumor proportion score status on treatment choices.

Dr Rotow on the Investigation of ABBV-637 Plus Osimertinib in EGFR-Mutated NSCLC

October 27th 2023

Julia Rotow, MD, discusses results from a first-in-human phase 1 study of the EGFR-targeting, BCL-XL–inhibiting antibody-drug conjugate ABBV-637 in combination with osimertinib in patients with relapsed/refractory, EGFR-mutated non–small cell lung cancer.

Dr. Rotow on Remaining Questions With Brigatinib in ALK+ NSCLC

January 31st 2020

Julia Rotow, MD, discusses remaining questions with brigatinib in ALK-positive non–small cell lung cancer.

Dr. Rotow on the Implications of Next-Generation ALK Inhibitors in NSCLC

January 31st 2020

Julia Rotow, MD, discusses the implications of next-generation ALK inhibitors in non–small cell lung cancer.

Dr. Rotow on First-Line Brigatinib Versus Crizotinib in ALK+ NSCLC

January 31st 2020

Julia Rotow, MD, discusses the utility of brigatinib versus crizotinib for the first-line treatment of patients with ALK-positive non

Dr. Rotow on Updated ALEX Trial Results in ALK+ NSCLC

January 17th 2020

Julia Rotow, MD, discusses updated data from the phase III ALEX trial in ALK-positive non–small cell lung cancer.

Dr. Rotow on Brigatinib Safety Profile in ALK+ NSCLC

January 2nd 2020

Julia Rotow, MD, discusses the safety profile of brigatinib in ALK-positive non–small cell lung cancer.